Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
December 21, 2023 16:00 ET | Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of...
Logo.png
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
November 29, 2023 17:41 ET | Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market...
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
November 27, 2023 09:00 ET | Biodexa Pharmaceuticals PLC
Cardiff , Nov. 27, 2023 (GLOBE NEWSWIRE) -- 27 November 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to...
Emergen logo.png
Global Intensity Modulated Radiotherapy (IMRT) Market Size to Reach USD 3.74 Billion in 2032 | Emergen Research
October 24, 2023 04:57 ET | Emergen Research
Vancouver, Oct. 24, 2023 (GLOBE NEWSWIRE) -- The global Intensity Modulated Radiotherapy (IMRT) market size was USD 2.21 Billion in 2022 and is expected to register a steady revenue CAGR of 5.4%...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
October 03, 2023 08:30 ET | Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma Biodexa Pharmaceuticals PLC, (Nasdaq:...
Interim results for the six months ended 30 June 2023
September 29, 2023 16:30 ET | Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
September 21, 2023 08:30 ET | Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
Research Nester Logo.jpg
Ultrasonic Aspirator Market revenue to surpass USD 257 Million by 2035, says Research Nester
August 24, 2023 07:30 ET | Research Nester
New York, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The global ultrasonic aspirator market size is predicted to grow at a CAGR of over ~6% from 2023 to 2035. The market is projected to garner a revenue of...
Transparency Market Research
Epilepsy Monitoring Devices Market to Exceed USD 737.0 Mn by 2031 to Grow at a CAGR of 4.6% Says, Transparency Market Research
August 17, 2023 06:04 ET | Transparency Market Research
Wilmington, Delaware, United States, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global epilepsy monitoring devices market is estimated to reach a value of US$ 737.0 Mn...
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
July 28, 2023 08:00 ET | Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the “Company”),  a clinical stage biopharmaceutical company...